Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$32.32
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Jul 30, 2026 | $-0.44 | $-0.07 | Beat +84.1% | $-0.07 | $86.24M | $103.55M | +20.1% | 1D Pre+2.4% | On-Day+9.5% | 1D Post+4.5% |
Q ended Mar 31, 2026 Reported May 6, 2026 | $-0.49 | $-0.49 | Met 0.0% | — | $79.23M | $83.68M | +5.6% | 1D Pre-3.6% | On-Day+0.6% | 1D Post-22.3% |
Q ended Dec 31, 2025 Reported Feb 26, 2026 | $-0.23 | $-0.08 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Beat +65.2% |
| — |
| $80.31M |
| $87.01M |
| +8.3% |
| 1D Pre+3.0% |
| On-Day+3.4% |
| 1D Post-7.2% |
Q ended Sep 30, 2025 Reported Nov 3, 2025 | $-0.51 | $-0.02 | Beat +96.1% | — | $71.14M | $83.04M | +16.7% | 1D Pre+5.3% | On-Day+1.9% | 1D Post+21.7% |